News

The company reported revenues of $82.85 million for the year ended December 31, 2008, compared to $44.34 million for the year ended December 31, 2007. The increase in

Eurand, a specialty pharmaceutical company, has received the FDA orphan drug designation for EUR-1073 in pediatric patients. EUR-1073 is a proprietary development product for the treatment of ulcerative

For the 12 months ended December 31, 2008, the company reported a net loss of $8 million, or $0.43 per share, compared to a net loss of $24.6

According to the company, the HemAway Seat is a painless, non-invasive, discreet, and easy-to-use hemorrhoid treatment device that alleviates the discomfort and agony of prolapsed internal hemorrhoids within

In its filing with the bankruptcy court, North American Scientific (NASM) cited that its bank, pursuant to its rights under certain lending agreements, had reduced the company’s borrowing

Dr Batchelor will lead the company’s pursuit of discovering and developing small molecules and biologics to guide cell fate for therapeutic purposes. Dr Batchelor brings more than 28

Advaxis, a development-stage biotechnology company, has submitted to the FDA its lead drug candidate, ADXS11-001, for orphan drug designation to treat invasive carcinoma of the cervix. The orphan

Aveo Pharmaceuticals, a biotechnology company, has initiated a Phase Ib/IIa clinical trial of AV-951 as monotherapy for the treatment of advanced non-small cell lung cancer. This new trial

US-based Celator Pharmaceuticals has treated the first patient in its Phase II multicenter, randomized, open-label clinical trial of CPX-351 liposome injection versus intensive salvage therapy in adult patients,